Journal ArticleDOI
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton,Robert B. Livingston,David H. Johnson,James R. Rigas,Michael R. Johnston,Charles Butts,Yvon Cormier,Glenwood D. Goss,Richard Inculet,Eric Vallières,Willard A Fry,Drew Bethune,Joseph Ayoub,Keyue Ding,Lesley Seymour,Barbara Graham,Ming-Sound Tsao,David R. Gandara,Kenneth A. Kesler,Todd L. Demmy,Frances A. Shepherd +20 more
TLDR
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.Abstract:
background We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non–small-cell lung cancer. methods We randomly assigned patients with completely resected stage IB or stage II non–smallcell lung cancer to vinorelbine plus cisplatin or to observation. The primary end point was overall survival; principal secondary end points were recurrence-free survival and the toxicity and safety of the regimen. results A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03). conclusions Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non–small-cell lung cancer.read more
Citations
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw,John Crowley,Kari Chansky,Dorothy J. Giroux,Patti A. Groome,Ramón Rami-Porta,Pieter E. Postmus,Valerie W. Rusch,Leslie H. Sobin +8 more
TL;DR: Suggestions include additional cutoffs for tumor size, with tumors >7 cm moving from T2 to T3; reassigning the category given to additional pulmonary nodules in some locations; and reclassifying pleural effusion as an M descriptor.
Journal ArticleDOI
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
TL;DR: The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
Jean Pierre Pignon,Hélène Tribodet,Giorgio V. Scagliotti,Jean-Yves Douillard,Frances A. Shepherd,Richard J. Stephens,Ariane Dunant,Valter Torri,Rafael Rosell,Lesley Seymour,Stephen G. Spiro,Estelle Rolland,Roldano Fossati,Delphine Aubert,Keyue Ding,David A. Waller,Thierry Le Chevalier +16 more
TL;DR: Postoperative cisplatin-based chemotherapy significantly improves survival in patients with non-small-cell lung cancer (NSCLC).
Journal ArticleDOI
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Ken A. Olaussen,Ariane Dunant,Pierre Fouret,Elisabeth Brambilla,Fabrice Andre,Vincent Haddad,E. Taranchon,Martin Filipits,Robert Pirker,Helmut Popper,R. Stahel,Laure Sabatier,Jean-Pierre Pignon,Thomas Tursz,Thierry Le Chevalier,Jean-Charles Soria +15 more
TL;DR: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ER CC1-positive tumors do not.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Revisions in the International System for Staging Lung Cancer
TL;DR: Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.
Journal ArticleDOI
Cancer Statistics, 2004
Ahmedin Jemal,Ram C. Tiwari,Taylor Murray,Asma Ghafoor,Alicia Samuels,Elizabeth Ward,Eric J. Feuer,Michael J. Thun +7 more
TL;DR: The American Cancer Society estimated the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival rates based on incidence data from National Cancer Institute and mortality data from the National Center for Health Statistics.
Journal Article
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
TL;DR: The results of this meta-analysis suggest that chemotherapy may have a role in treating non-small cell lung cancer, and reached conventional levels of significance when used with radical radiotherapy and with supportive care.
Journal ArticleDOI
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Rodrigo Arriagada,Bengt Bergman,Ariane Dunant,Le Chevalier T,J.P. Pignon,Johan Vansteenkiste +5 more
TL;DR: Cisplatin-based adjuvant chemotherapy improves survival among patients with completely resected non-small-cell lung cancer and had a significantly higher survival rate than those assigned to observation.
Related Papers (5)
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial
Jean-Yves Douillard,Rafael Rosell,Mario De Lena,Francesco Carpagnano,Rodryg Ramlau,Jose Luis Gonzáles-Larriba,Tomasz Grodzki,José Rodrigues Pereira,Alain Le Groumellec,Vito Lorusso,Claude Clary,Antoni Torres,Jabrail Dahabreh,Pierre Jean Souquet,Julio Astudillo,Pierre Fournel,Angel Artal-Cortes,Jacek Jassem,Leona Koubkova,Patricia His,Marcello Riggi,Patrick Hurteloup +21 more